Dr. Richard Chen, Chief Scientific Officer, Personalis, Inc. to Present Data and Discuss Tumor Immuno-genomics and Personalized Vaccines Solutions at 2017 Neoantigen Summit

On December 8, 2017 Personalis, Inc., a leading provider of advanced genomic sequencing and analytics to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies, reported that the company’s Chief Scientific Officer (CSO), Dr. Richard Chen, will be speaking at the upcoming Neoantigen Summit, being held in Boston, MA from November 14-16, 2017 (Press release, Personalis, DEC 8, 2017, View Source [SID1234522469]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation entitled, "From Sample to Neoantigens for Vaccines: Key Challenges and Solutions" will cover topics including:

cfDNA Neoantigens: dealing with tumor heterogeneity
Improving neoantigen identification
Elaborating tumor microenvironment (TME), immuno-modulators and vaccine response biomarkers
Overcoming poor sample quality and quantity for NGS sequencing
Addressing sequencing coverage gaps that can harbor neoantigens
Validation and regulatory issues on the way to commercialization
Central to this presentation will be Personalis’ ACE ImmunoID Platform. The platform enables the comprehensive characterization of a tumor’s immuno-genomics including neoantigens, the tumor microenvironment, HLA, immuno-modulators and mechanisms of tumor escape to aid rational vaccine design.

"We are continuing to innovate to help our customers build safe, effective, and scalable personalized cancer vaccines. In this talk we will discuss how our ACE ImmunoID platform has been designed to overcome key challenges in personalized cancer vaccine development process starting from a tumor sample to neoantigen identification and rational vaccine design," said Dr. Richard Chen, CSO at Personalis.

Personalis will also be exhibiting during the Neoantigen Summit. Representatives will be available to answer questions about the company’s neoantigen identification and immuno-genomics capabilities.